| NCT06980649 | Study of BHV-1300 in Graves' Disease | RECRUITING | PHASE1 | 2025-08-21 | 2026-03 | 2025-11 |
| NCT07054684 | Study of BHV-1400 in IgA Nephropathy | RECRUITING | PHASE1 | 2025-07-30 | 2026-07 | 2026-07 |
| NCT06976268 | A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | RECRUITING | PHASE2, PHASE3 | 2025-05-28 | 2027-09 | 2027-08 |
| NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-03-20 | 2029-03 | 2029-03 |
| NCT06603623 | Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine | COMPLETED | PHASE2 | 2024-10-10 | 2025-03-28 | 2025-03-24 |
| NCT06423781 | Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) | ENROLLING_BY_INVITATION | PHASE2 | 2024-08-01 | 2027-11 | 2027-11 |
| NCT06443463 | Long-term Safety and Tolerability of BHV-7000 | ENROLLING_BY_INVITATION | PHASE2 | 2024-07-30 | 2027-01 | 2026-12 |
| NCT06423794 | BHV-7000 Open-Label Extension Bipolar Mania Study | TERMINATED | PHASE2 | 2024-06-24 | 2025-04-25 | 2025-04-25 |
| NCT06425159 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | RECRUITING | PHASE2, PHASE3 | 2024-06-20 | 2027-07 | 2026-07 |
| NCT06419608 | Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-05-28 | 2025-12 | 2025-11 |
| NCT06419582 | BHV-7000 Acute Treatment of Bipolar Mania | COMPLETED | PHASE2, PHASE3 | 2024-05-28 | 2025-01-30 | 2025-01-15 |
| NCT06309966 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | RECRUITING | PHASE2, PHASE3 | 2024-05-13 | 2026-02 | 2026-01 |
| NCT06384807 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2024-04-22 | 2028-02 | 2028-02 |
| NCT06132893 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | RECRUITING | PHASE2, PHASE3 | 2024-03-14 | 2026-12 | 2026-12 |
| NCT05337553 | A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-06 | 2026-01 | 2024-09-25 |
| NCT04634435 | Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients | COMPLETED | PHASE1 | 2021-10-21 | 2025-01-10 | 2025-01-10 |
| NCT04708834 | Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder | ENROLLING_BY_INVITATION | PHASE3 | 2021-03-30 | 2026-06 | 2026-06 |
| NCT04693351 | Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder | COMPLETED | PHASE3 | 2021-01-29 | 2025-04-29 | 2025-04-29 |
| NCT04641143 | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-12-22 | 2025-11 | 2025-11 |
| NCT03952806 | Study of BHV-3241 in Participants With Multiple System Atrophy | COMPLETED | PHASE3 | 2019-07-29 | 2022-06-30 | 2021-07-29 |
| NCT03701399 | Troriluzole in Adult Participants With Spinocerebellar Ataxia | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-03-08 | 2025-10 | 2022-02-18 |
| NCT03829241 | Randomized Trial of Adult Participants With Generalized Anxiety Disorder | COMPLETED | PHASE3 | 2019-02-19 | 2020-05-08 | 2020-01-14 |
| NCT03605667 | Study of BHV-4157 in Alzheimer's Disease | COMPLETED | PHASE2 | 2018-07-31 | 2021-12-23 | 2020-12-15 |
| NCT03520517 | Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS | COMPLETED | PHASE1 | 2018-02-02 | 2018-10-08 | 2018-10-08 |
| NCT03299166 | Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2017-12-19 | 2026-03 | 2020-06-02 |
| NCT02960893 | Trial in Adult Participants With Spinocerebellar Ataxia (SCA) | COMPLETED | PHASE2, PHASE3 | 2016-12-15 | 2024-09-20 | 2017-08-18 |